Tele: 561.316.3330
Breaking Medical Device News

Sunday, October 17, 2021
HomeACQUISITIONS and MERGERSLaborie Medical Technologies Acquires Pelvalon

Laborie Medical Technologies Acquires Pelvalon

Innovative product added to Laborie's growing portfolio that treats underserved patient community

9 of the Highest Paying Travel Nursing Specialties

The highest paying travel nursing specialties tend to offer significantly higher pay rates and benefits than their non-traveling counterparts. Learn More.

Involved in a Car-Truck Collision? Here’s How to Deal With the Aftermath

It can be challenging to know how to proceed when the unthinkable happens, and you are involved in a car-truck collision. You may have...

Why Every Healthcare Organization Should Embrace A Lean Approach

Quality, efficiency, and safety determine the success of a business in any domain. The healthcare industry is not an exception. Rather, providers need to...

How Advancements in Technology is Changing the Medical Industry

As with many industries, the healthcare industry is growing pretty rapidly. As technology advances, the medical industry has benefitted more than any other. Medical...

How Healthcare Professionals Can Benefit From Deployable Field Hospitals

Read on to find out what deployable field hospitals are and at least five ways healthcare professionals can benefit from deployable field hospitals.

6 Tips That Will Help You Pass Your USMLE Exam

It's that time of year again. If you are a medical student, then that means it is time to take your USMLE exam. This...

Laborie Medical Technologies Corp. (Laborie) a specialist medical technology company, announced today that it has acquired Pelvalon, Inc., a privately held medical device company located in Redwood City, CA.

Pelvalon has developed an innovative product called the Eclipse™ System, a non-surgical, patient-controlled device for women suffering from fecal incontinence (FI). FI is a pelvic floor disorder that affects one in ten women. The Eclipse has a compelling clinical profile validated in multiple studies, is FDA-cleared and has established reimbursement. The product is simple, safe and effective and its reputation has spurred demand from numerous healthcare professionals and patients across the country.

“Laborie’s mission every day is to operate as a world-class specialist medical company making and advancing technologies that preserve and restore human dignity,” said Michael Frazzette, President & CEO of Laborie. “Our mission is well served by the addition of Eclipse™ to help patients who suffer from this difficult condition.”

“I am grateful for the dedicated work of my colleagues to bring the therapy to this point, and we are delighted that Laborie will be able to scale and deliver Eclipse™ to the doctors and patients who need it,” said Miles Rosen, Pelvalon Founder and CEO. “Laborie’s mission aligns perfectly with this technology.”

“Patricia Industries is committed to supporting Laborie in its mission to provide patients and healthcare professionals with innovative and effective therapeutic and diagnostic technologies that preserve and restore human dignity,” said Yuriy Prilutskiy, Head of Patricia Industries North America, a part of Investor AB, and owner of Laborie. “This acquisition further supports Laborie’s long-term growth, leverages Patricia Industries’ healthcare and life sciences expertise and aligns with our organization’s purpose of creating value for people and society by building strong and sustainable businesses.”

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

spot_img

DON'T MISS

Cochlear Announces FDA Approval and Clearance of first-of-its-kind Remote Care Capabilities for Nucleus and Baha Systems

The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution is the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.

Alpha Tau Receives FDA’s Breakthrough Device Designation for the RX of Recurrent Glioblastoma Multiforme

"As GBM is such a terrible disease, it is critical that we find new solutions for these patients, and we are thrilled that receipt of the FDA's Breakthrough Device Designation will allow us to expedite our clinical collaborations with leading cancer centers in the U.S. and across the world, and to bring new hope for GBM patients.

FDA Announces Signing of Domestic Mutual Reliance Agreements with California, Florida, Utah and Wisconsin

These Mutual Reliance agreements facilitate a coordinated effort between the FDA and individual states with goals to reduce human foodborne illness outbreaks, reduce duplication of regulatory oversight and increase public health protection by focusing on areas of higher risk.

SyncThink Receives Second FDA Clearance for EYE-SYNC Platform; the First Mobile, Rapid Test for Concussion

EYE-SYNC previously received the prestigious Breakthrough Device Designation from the FDA in 2019, following the initial clearance and commercialization of the technology platform in 2017.

Our Sister Publication: Biotechnology News Magazine

By using this website you agree to accept Medical Device News Magazine Privacy Policy